This is a new Research Program at the Stanford Cancer Center that has been established to promote collaborations among clinical and basic scientists to develop novel diagnostic and therapeutic approaches for cancer. The program consists of 41 members from 12 departments and 3 schools within the University and brings together chemists, biologists, statisticians and translational and clinical researchers with a common interest in the development of new cancer therapies. The Program has five major components: target identification and validation;drug discovery and delivery;mechanisms of drug action;molecular diagnostics;and clinical translational research. Research by program members has identified a novel synthetic chemistry approach to overcome taxol drug resistance, utilized carbon nanotechnology for the development of targeted delivery of Taxol (paclitaxel) or Doxorubicin, discovered that the inhibition of alpha PKC protects against breast cancer metastasis, defined genetic mechanisms for regulation of the MDR1/ABCB1 gene, developed a new technology for the nanoscale measurement of proteins for molecular diagnostics, applied high-throughput technologies to identify new agents that target the hedgehog pathway, and identified novel adenoviral based vectors for gene delivery to the liver. The Program is highly interactive through annual retreats, monthly research meetings, bi-annual faculty meetings, bi-annual student-sponsored symposia and invited speakers and symposia with pharmaceutical companies. The Program has catalyzed interactions leading to multi-investigator program awards including: a Leukemia and Lymphoma SCOR grant, a Department of Defense grant and an NIH Major Equipment Instrument Grant. Dr. Dean Felsher, Program Leader, is a physician scientist who is a leader in elucidating mechanisms of oncogene addiction through the use of transgenic animal models of lymphoma, hepatoma, osteosarcoma and lung adenocarcinoma. Dr. Branimir Sikic, Program Co-Leader, is a physician scientist whose research focuses on the pharmacology of drug resistance and who has been instrumental in implementing Phase I and II clinical trials. This program has the goal of conducting first-in- human Phase I trials of novel agents based on the best science.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475446
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$13,987
Indirect Cost
$4
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Denny, Sarah K; Yang, Dian; Chuang, Chen-Hua et al. (2016) Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility. Cell 166:328-42
Li, Jian; Pfeffer, Suzanne R (2016) Lysosomal membrane glycoproteins bind cholesterol and contribute to lysosomal cholesterol export. Elife 5:
Chuang, Jody C; Shrager, Joseph B; Wakelee, Heather A et al. (2016) Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clin Ther 38:1567-76
Wanigatunga, Amal A; Sourdet, Sandrine S; LaMonte, Michael J et al. (2016) Physical impairment and body weight history in postmenopausal women: the Women's Health Initiative. Public Health Nutr 19:3169-3177
Zanganeh, Saeid; Hutter, Gregor; Spitler, Ryan et al. (2016) Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol 11:986-994
Hiniker, Susan M; Reddy, Sunil A; Maecker, Holden T et al. (2016) A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys 96:578-88
Grüner, Barbara M; Schulze, Christopher J; Yang, Dian et al. (2016) An in vivo multiplexed small-molecule screening platform. Nat Methods 13:883-9
Chen, Frank W; Sundaram, Vandana; Chew, Thomas A et al. (2016) Advanced Stage Colorectal Cancer in Persons Younger Than 50 Years not Associated With Longer Duration of Symptoms or Time to Diagnosis. Clin Gastroenterol Hepatol :
Zhu, Gefei Alex; Lira, Ruth; Colevas, Alexander Dimitrios (2016) Discordance in routine second opinion pathology review of head and neck oncology specimens: A single-center five year retrospective review. Oral Oncol 53:36-41
Brady, Jennifer J; Chuang, Chen-Hua; Greenside, Peyton G et al. (2016) An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency. Cancer Cell 29:697-710

Showing the most recent 10 out of 278 publications